Magnitude Biosciences secures €1.5 million investment to scale in-vivo drug discovery platform
Magnitude Biosciences, a specialist contract research organisation (CRO) and Durham University spinout, has secured €1.5 million (£1.3 million) in funding to accelerate the commercialisation of VivoScan, its proprietary in vivo high-throughput screening (HTS) platform. Northstar Ventures led the rou
<p>Magnitude Biosciences, a specialist contract research organisation (CRO) and Durham University spinout, has secured €1.5 million (£1.3 million) in funding to accelerate the commercialisation of VivoScan, its proprietary in vivo high-throughput screening (HTS) platform. Northstar Ventures led the rou</p>